Name and Surname: Mario Vincenzo Di Iorio
Date and place of birth: 15th August 1975, Lucera, FG (ITALY)
Work Address: Molecular Medicine Department, University of
Padova, Via Gabelli, 63, 35121 Padova

46 Pubblications; 2186 Citations, H-INDEX: 18

2003 Scuola di Specializzazione in “Genetica Applicata” (3 years post-doctoral
degree) at University of Rome “La Sapienza”, Italy (70/70 with honors).
1999 Italian degree in Biological Science (5 years course) at University of Rome
“La Sapienza”, Italy (110/110 with honors).
1994 Maturita’ Classica at Liceo Ginnasio Statale “R. Bonghi” (Lucera, FG).
AWARDS, HONORS, POSITIONS AND WORK EXPERIENCE
2021 Associate Professor of Genetic and Microbiology at the Department of
Molecular Medicine, University of Padua
2020 Managing Biologist (Level I), Clinical Genetics Unit, University Hospital
of Padua.
2018 Renewal of AFM Grant (20687): “Advanced therapy medicinal products
for the treatment of ocular defects in Ectrodactyly-Ectodermal Dysplasia-
Clefting (EEC) syndrome”.
2018 Recipient of the grant from the Italian Ministry of Health (RF-2016-
02361159): “Advanced therapy medicinal products for the treatment of
ocular defects in Ectrodactyly-Ectodermal Dysplasia-Clefting (EEC)
syndrome”.
2017 Award of National Academic Scientific Qualification to the functions of
associate professor for “Genetica (05/I1)” and “Scienze delle professioni
sanitarie e delle tecnologie mediche applicate (06/N1)”.
2017 Recipient of AFM Grant (20687): “Advanced therapy medicinal products
for the treatment of ocular defects in Ectrodactyly-Ectodermal Dysplasia-
Clefting (EEC) syndrome”.
2015-2018 Member of the “Technical and Sanitary Committee” of the Ministry of
Health, Roma.
2015 Recipient of ex-60% funds (60A07-5935/15): "Accelerated ageing and
defects in proliferation, differentiation and stratification of p63-mutant-
stem cells are restored through a siRNA-based approach: a promising
therapeutic option for corneal disorders in EEC patients".
2015 Recipient of the grant “Progetti di Ricerca di Ateneo” (PRAT
CPDA159895): “Promising gene-based therapeutic approaches to correct
ocular surface disorders in EEC patients”, University of Padova.
2014 Recipient of ex-60% funds (60A07-4372/14): "Gene therapy approach
through siRNA against p63 mutants to correct ocular surface disorders in
Ectrodactyly-Ectodermal displasya-Clefting (EEC) syndrome".
2014: Collaborator of the grant “Progetti di Ricerca di Ateneo” (PRAT
CPDA132881): “Innovative method for the treatment of total limbal stem
cells deficiency through a tissue-engineered hemicornea: animal model”,
University of Padova.
2013 Recipient of the grant from the Associazione RP Triveneto: “Retinitis
Pigmentosa: clinical and molecular diagnosis of disease genes through
Next Generation Sequencing (NGS) and developing of innovative cell and
gene therapy strategies.”.
2013-present Member of the Ethics Committee of “Istituto Oncologico Veneto-IRCCS”
(IOV), Padova.
2013-present Adjunct professor of Genetic and Microbiology at Molecular Medicine
Department, University of Padova.
2012-present Executive Biologist (Level I), Microbiology and Virology Unit, Azienda
Ospedaliera, Padova: co-responsible of the Quality Management.
2012-2016 Collaborator and Quality Control consultant at the Cell Factory of
Fondazione Banca degli Occhi del Veneto-Onlus (Venice, Italy).

Download Curriculum_Di Iorio.pdf

Download Pubblicazioni_Di Iorio.pdf

1. Advanced Therapy Medicinal Products for the Treatment of Ocular Defects in Ectrodactyly-Ectodermal Dysplasia-Clefting (EEC) Syndrome through Viral and/or Non-Viral Gene Therapy Approaches against p63 gene.


2. Tissue Engineering and Stem Cell-Based Therapies for the Treatment of Patients Affected by Bilateral Limbal Stem Cell Deficiency: Preparation of Hemicorneas Obtained by Oral Mucosa Stem Cells expanded on stromal scaffolds (human keratoplasty lenticules) according with good manufacturing practices (GMPs).

*
3. Molecular Diagnosis of Gene Diseases by means of Next Generation Sequencing (NGS) and Development of Innovative Strategies Based on Cell and Gene Therapies for Retinal Diseases.*